Table 1. Baseline demographic and clinical characteristics of patients consented for blood draw.

	Limited stage disease N=29 (%)	Metastatic disease N=25 (%)
Gender -Male -Female	13 (45) 16 (55)	13 (52) 12 (48)
Median age (yrs.)	59	59
Race -White -Black -Hispanic -Asian -Unknown	6 (21) 6 (21) 15 (52) 1 (3) 1 (3)	4 (16) 8 (32) 11 (44) 1 (4) 1 (4)
Sidedness -Right -Left	8 (28) 21 (72)	9 (36) 16 (64)
KRAS -Mutated -Wild Type -Not performed	3 (10) 6 (21) 20 (69)	10 (40) 10 (40) 5 (20)

This table lists the baseline demographic and clinical characteristics of 54 patients who consented to blood draw for analysis of ERCC1 kinetics in PBMC. The patients are divided by stage of malignancy into limited stage (clinical stage II-III) and metastatic disease (clinical stage IV). Race was determined by patient self-identification. Based on site of origin of primary tumor, patients were categorized into right (cecum, ascending colon, hepatic flexure, upto mid-transverse colon) or left (distal transverse colon, splenic flexure, descending colon, sigmoid colon and rectum) sided. KRAS mutation status was identified, and as expected was performed less frequently in limited stage disease.